Form 4: CareDx CEO Hanna Boosts Stake with RSU Grants

CareDx, Inc. CEO John Walter Hanna JR reported the acquisition of 200,132 shares through RSU and PRSU awards, alongside a disposition of 13,694 shares for tax withholding.

Summary

• John Walter Hanna JR, President and CEO, and Director of CareDx, Inc. (CDNA), reported transactions on February 2, 2026.
• Acquired 162,500 shares of common stock through Restricted Stock Units (RSUs) at a price of $0.
• Acquired an additional 37,632 shares of common stock through Performance Restricted Stock Units (PRSUs) at a price of $0, following the achievement of certain performance criteria.
• Disposed of 13,694 shares of common stock at $20.42 per share to cover tax withholding obligations related to the PRSU vesting.
• Following these transactions, Hanna directly beneficially owns 783,843 shares of CareDx, Inc. common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, reflecting the CEO's continued equity alignment with the company and the achievement of performance targets for PRSU vesting, which indicates operational success.

Positives

• CEO John Walter Hanna JR acquired a significant number of shares (200,132 total) through RSU and PRSU awards, indicating continued equity alignment with shareholder interests.
• The vesting of 37,632 Performance Restricted Stock Units (PRSUs) signifies the achievement of certain performance criteria by the company, as certified by the Compensation and Human Capital Committee.

Negatives

• A disposition of 13,694 shares occurred to satisfy tax withholding obligations, which is a common practice but reduces the CEO's direct share count.

Future Outlook

The 162,500 Restricted Stock Units (RSUs) will vest in installments, with one-third vesting on April 6, 2027, and the remainder vesting quarterly over the subsequent eight quarters, fully vesting on the third anniversary of April 6, 2027, contingent on continuous employment.

Industry Context

StockSavvy.ai notes that executive equity grants and performance-based awards are standard practices in the biotechnology and diagnostics industry, aligning management incentives with long-term company performance and shareholder value creation. The vesting of PRSUs suggests the company met specific operational or financial targets.

Comparison to Industry Standards

• The structure of RSU and PRSU awards, including multi-year vesting schedules, is consistent with executive compensation practices observed in comparable life sciences companies such as Illumina (ILMN) or Guardant Health (GH), aiming to retain key talent and incentivize sustained performance.
• The tax withholding disposition is a routine event for equity compensation, aligning with standard practices across industries when restricted stock vests.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders through significant equity grants.
• Employees: The achievement of performance criteria for PRSUs could signal positive company performance, potentially boosting employee morale.

Next Steps

• Continued vesting of 162,500 RSUs, with the next tranche vesting on April 6, 2027.

Key Dates

Recommendation

While the CEO's increased equity stake and the achievement of performance targets are positive indicators, a Form 4 filing primarily details executive compensation and ownership changes. It does not provide comprehensive financial or operational data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this information in conjunction with broader financial reports and market analysis.

Keywords

CareDx, CDNA, Form 4, Insider Trading, Restricted Stock Units, Performance Shares, CEO Stock, Executive Compensation, Equity Grant, Stock Ownership